D-0020-2022 Class II Terminated
FDA drug recall D-0020-2022 was initiated by American Health Packaging on Sep 17, 2021 and is designated Class II. Reason for recall: Failed Dissolution Specifications: results were above specification. The recall status is terminated (terminated Jun 8, 2023). Affected quantity: 2,266 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 27, 2021
- Initiation Date
- Sep 17, 2021
- Termination Date
- Jun 8, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2,266 cartons
Product description
GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx only, Manufactured by: Patheon Pharmaceuticals Inc., Cincinnati, OH 45237; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054. Carton NDC#: 68084-295-21 (Individual Dose NDC: 68084-295-11)
Reason for recall
Failed Dissolution Specifications: results were above specification.
Distribution pattern
Nationwide within the USA
Code information
Lot #: 194141, Exp. Date 03/31/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0020-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026